February 28, 2015 1:10 PM ET


Company Overview of Speedel Holding AG

Company Overview

Speedel Holding AG was acquired by Novartis AG. Speedel Holding AG, a biopharmaceutical company, develops renin inhibitors for treatment of cardiovascular and metabolic diseases. The company’s products include SPP100, which is used for the treatment of hypertension, and in Phase III clinical trial for the treatment of diabetic nephropathy; SPP200, a Phase II completed clinical trial product for the treatment of graft occlusion in chronic hemodialysis; and SPP301, a Phase II completed clinical trial product for diabetic nephropathy. Its products also comprise SPP635, a Phase IIa clinical trial product for hypertension and end organ protection; SPP676, a Phase I clinical trial product for hype...

Forum 1

Novartis Campus

Basel,  4056


Founded in 1998

84 Employees


41 61 324 11 11


41 61 324 80 01

Key Executives for Speedel Holding AG

Speedel Holding AG does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Abbott Laboratories SA Europe
Amal Therapeutics SA Europe
Ginsana SA Europe
Ferring Holding SA Europe
Laboratoires Plan SA Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Speedel Holding AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.